Cancer is extremely common and in many situations a truly frightening disease, but the psychological aspects and effects have frequently been ignored. Patrice Guex reviews current thinking on the subject of possible psychosomatic causes of cancer, on the emotional or psychological reactions that it provokes, and on the medical treatment available. Illustrated with 11 case histories, this work aims to deal with the reactions of cancer patients to their illness, and the ways in which they can be helped in the hospital setting, at the same time having regard for their human dignity. In the context of a multidisciplinary approach that takes account of medical treatments as well as psychological interventions, the author suggests better ways of communicating in order to provide a therapeutic partnership between carer and client. Every aspect of cancer care, including pain relief, psycho-pharmology and complementary medicine, is considered, paying special attention to the needs of terminal patients and their carers.

Translated by:
Heather Goodare

The development of drug-resistant cancers is considered to be the most significant obstacle to the cure of cancer today. Nearly half of all patients with cancer suffer from tumours that are intrinsically resistant to chemotherapy, and most of the remaining half develop drug resistance during the course of their treatment. This book reviews the mechanisms and clinical implications of drug resistance in cancer with unrivalled authority. Chapters cover topics of current clinical concern, including multiple drug resistance and its reversal, topoisomerase drugs, apoptosis, dose intensity and escalation, gene therapy and haematopoietic support. The authors are among the leading clinicians and investigators in the field. These authoritative volumes in this series are intended for a wide audience of clinicians and researchers with an interest in the applications of biomedical science to the understanding and management of cancer.

Treatment of Cancer is a multi-author work and comprehensive guide on modern cancer treatment that aims to give clinician and student alike the framework for an integrated approach to patient care, including radiotherapy, chemotherapy, and surgery. Much information is presented in tables and charts for easy assimilation, and clear algorithms for patient pathways are included to make decisions straightforward while allowing for sound clinical judgement.

This 2006 book examines the interaction of economics and the delivery of cancer care in the global context. It analyses the causes of tension between those paying for care, those providing the care and those marketing drugs and devices. The concept and requirement for rationing is examined in different economic environments. As cancer increases in incidence and prevalence, the economics of providing care becomes a more important subject than ever before. Written by a leading health economist and oncologist, this was the first comprehensive book on the economics of cancer care continues to be of interest to health professionals and policy makers alike.

This 1996 volume reviewed advances in the field of human tumour immunology, particularly in relation to the potential for immune intervention in preventing or treating tumours. The editors and contributors, all prominent workers in the field, survey advances in the understanding of the relationship between the cancer cell and the immune response at the time of publication. Chapters review in depth the function of immune surveillance and mechanisms of tumour immunity, the role of T lymphocytes and oncogenes in the immune response to cancer, and the potential for immunotherapy of cancer. Areas of tumour immunology that were new at the time of this book's publication are presented, including progress in the development of tumour vaccines with particular reference to melanoma. The volumes in this series are intended for a wide audience of clinicians and researchers with an interest in the applications of biomedical science to the understanding and management of cancer.

Interferon was first discovered in 1957. Over the last five years it has become almost a household word. Many believe it to be a drug with already proven efficacy against cancer and viral infection. The media has distorted any cool scientific view of the data available. We have learned much about the complexity of the interferon system. We know some of the switches involved in interferon gene expression and its secretion by virally and immune stimulated cells. We also know that it binds to a cell surface receptor, mediating its complex effects on target cells by a series of second messengers. The advent of the new techniques of modern molecular biology, such as monoclonal antibodies and gene cloning, has had tremendous impact on the rate of acquisition of knowledge. Such techniques have provided us with almost unlimited quantities of highly purified interferon for clinical trial in patients with a spectrum of infectious and malignant diseases. The information we have gathered raises many more questions. Why should there be several families of interferon genes? What is their true physiolo gical role? How are they interrelated functionally? Interferon is clearly a cellular hormone providing a means of communication between cells. fhether it has clinical value in the management of patients with diseased cells remains to be seen. This book sum marises our current knowledge of interferons as possible an- cancer agents. It is clear interferon is no penicillin for cancer."

This 1996 volume reviewed advances in the field of human tumour immunology, particularly in relation to the potential for immune intervention in preventing or treating tumours. The editors and contributors, all prominent workers in the field, survey advances in the understanding of the relationship between the cancer cell and the immune response at the time of publication. Chapters review in depth the function of immune surveillance and mechanisms of tumour immunity, the role of T lymphocytes and oncogenes in the immune response to cancer, and the potential for immunotherapy of cancer. Areas of tumour immunology that were new at the time of this book's publication are presented, including progress in the development of tumour vaccines with particular reference to melanoma. The volumes in this series are intended for a wide audience of clinicians and researchers with an interest in the applications of biomedical science to the understanding and management of cancer.

The Advances in Cancer Research series provides invaluable information on the exciting and fast-moving field of cancer research. This volume stands as the first ever thematic volume in the series, focusing on the topic of genomics in cancer drug development. The chapters included in this book represent the cutting-edge information in the field and span such topics as Mass Spectrometry: Uncovering the Cancer Proteome for Diagnostics; Biomarker Discovery in Epithelial Ovarian Cancer by Genomic Approaches; The Application of siRNA Technology to Cancer Biology Discovery; Ribozyme Technology for Cancer Gene Target Identification and Validation; Cancer Cell-Based Genomic and Small Molecule Screens; Tumour Antigens as Surrogate Markers and Targets for Therapy and Vaccines; Practices and Pitfalls of Mouse Cancer Models in Drug Discovery; Biomarker Assay Translation from Discovery to Clinical Studies in Cancer Drug Development - Quantification of Emerging Protein Biomarkers; Molecular Optical Imaging of Therapeutic Targets of Cancer; Cancer Drug Approval in the United States, Europe and Japan.

This 2006 book examines the interaction of economics and the delivery of cancer care in the global context. It analyses the causes of tension between those paying for care, those providing the care and those marketing drugs and devices. The concept and requirement for rationing is examined in different economic environments. As cancer increases in incidence and prevalence, the economics of providing care becomes a more important subject than ever before. Written by a leading health economist and oncologist, this was the first comprehensive book on the economics of cancer care continues to be of interest to health professionals and policy makers alike.

The development of drug-resistant cancers is considered to be the most significant obstacle to the cure of cancer today. Nearly half of all patients with cancer suffer from tumours that are intrinsically resistant to chemotherapy, and most of the remaining half develop drug resistance during the course of their treatment. This book reviews the mechanisms and clinical implications of drug resistance in cancer with unrivalled authority. Chapters cover topics of current clinical concern, including multiple drug resistance and its reversal, topoisomerase drugs, apoptosis, dose intensity and escalation, gene therapy and haematopoietic support. The authors are among the leading clinicians and investigators in the field. These authoritative volumes in this series are intended for a wide audience of clinicians and researchers with an interest in the applications of biomedical science to the understanding and management of cancer.

The street-wise patient's guide to surviving cancer.How to be an active, organised, informed, and welcomed patient.The author is an internationally-famous cancer doctor. Former Chief, World Health Organisation. Cancer Programme. How to survive, and live with, cancer.iE Short, sharp practical guide.iE Shows patients how to can take control of their care. iE How to get the system to work for you. iE Gives 100 advisory websites, with expert notes. iE Absolutely up-to-date.

Treatment of Cancer is a multi-author work and comprehensive guide on modern cancer treatment that aims to give clinician and student alike the framework for an integrated approach to patient care, including radiotherapy, chemotherapy, and surgery. Much information is presented in tables and charts for easy assimilation, and clear algorithms for patient pathways are included to make decisions straightforward while allowing for sound clinical judgement.